Patents Assigned to Ondek Pty. Ltd.
-
Patent number: 10130704Abstract: The present invention relates to the field of preventing or reducing incidence or severity of an allergic immune response, and compositions for preventing or reducing incidence or severity of an allergic immune response. For example, the present invention provides compositions comprising inactivated and/or killed cells of Helicobacter pylori or a cell lysate thereof, and methods and/or uses thereof for delaying or preventing or interrupting or slowing onset of one or more allergic conditions in a subject.Type: GrantFiled: December 16, 2016Date of Patent: November 20, 2018Assignee: ONDEK PTY LTDInventors: Mohammed Benghezal, Barry Marshall, Alma Fulurija, Senta Walton
-
Patent number: 9555104Abstract: The present invention relates to the field of preventing or reducing incidence or severity of an allergic immune response, and compositions for preventing or reducing incidence or severity of an allergic immune response. For example, the present invention provides compositions comprising inactivated and/or killed cells of Helicobacter pylori or a cell lysate thereof, and methods and/or uses thereof for delaying or preventing or interrupting or slowing onset of one or more allergic conditions in a subject.Type: GrantFiled: June 20, 2014Date of Patent: January 31, 2017Assignee: Ondek Pty LtdInventors: Mohammed Benghezal, Barry Marshall, Alma Fulurija, Senta Walton
-
Patent number: 9115363Abstract: The present invention relates to a gene expression and eradication system for Helicobacter pylori (H. pylori). In particular, the present invention relates to a genetic construct comprising, in the 5?-3? direction: (a) a promoter sequence and (b) a DNA sequence of interest, wherein the promoter sequence comprises a polynucleotide sequence capable of regulating expression of the DNA sequence of interest in Helicobacter pylori and wherein said promoter sequence is modified to comprise a tetracycline (tet) operator sequence.Type: GrantFiled: March 9, 2012Date of Patent: August 25, 2015Assignee: Ondek Pty LtdInventors: Mohammed Benghezal, Aleksandra Weronika Debowski, Miriam Sehnal, Yakhya Dieye, Se-Hoon Park, Barry Marshall
-
Patent number: 8992935Abstract: The present invention relates to a means of controlling infection persistence of Helicobacter pylori (H. pylori). In particular, the present invention relates to an isolated, genetically modified Helicobacter pylori comprising a functional urease, wherein the contiguous amino acid sequence between amino acid 529 and amino acid 555 of SEQ ID NO:1 is altered to produce said modified Helicobacter pylori which is unable to establish or maintain a persistent infection.Type: GrantFiled: June 24, 2011Date of Patent: March 31, 2015Assignee: Ondek Pty. Ltd.Inventors: Mohammed Benghezal, Tobias Schoep, Alma Fulurija, Douglas E. Berg, Barry J. Marshall
-
Patent number: 8790909Abstract: The present invention relates to strains of Helicobacter pylori useful for the delivery of biologically active agents. In particular, the present invention provides an isolated strain of H. pylori having: (a) low pathogenicity; (b) ability to naturally transform; and (c) ability to colonise mouse stomach mucosa without host adaptation.Type: GrantFiled: June 3, 2010Date of Patent: July 29, 2014Assignee: Ondek Pty. Ltd.Inventors: Mohammed Benghezal, Alma Fulurija, Wei Lu, Hans-Olof Nilsson, Barry J. Marshall
-
Patent number: 8715929Abstract: The present invention relates to synthetic operons. In particular, the present invention relates to a synthetic operon for integration into a bacterial chromosome of a bacterium comprising a promoter operably-linked to at least two genes, wherein at least one gene is a gene of interest and at least one gene is a gene essential to said bacterium.Type: GrantFiled: June 25, 2010Date of Patent: May 6, 2014Assignee: Ondek Pty. Ltd.Inventors: Mohammed Benghezal, Yakhya Dieye, Carola Schwann, Miriam Sehnal, Alma Fulurija, Barry J. Marshall
-
Publication number: 20130259888Abstract: The present invention relates to a means of controlling infection persistence of Helicobacter pylori (H. pylori). In particular, the present invention relates to an isolated, genetically modified Helicobacter pylori comprising a functional urease, wherein the contiguous amino acid sequence between amino acid 529 and amino acid 555 of SEQ ID NO:1 is altered to produce said modified Helicobacter pylori which is unable to establish or maintain a persistent infection.Type: ApplicationFiled: June 24, 2011Publication date: October 3, 2013Applicant: ONDEK PTY LTDInventors: Mohammed Benghezal, Tobias Schoep, Alma Fulurija, Douglas E. Berg, Barry J. Marshall
-
Patent number: 8420374Abstract: Helicobacter based preparations comprising a pharmacologically active molecule of interest are disclosed, as well as methods of preparing and using said preparations. In particular, Helicobacter pylori vectors, vector plasmids and recombinant cells that include a sequence encoding a pharmacologically active molecule of interest useful in therapeutic treatments and/or vaccination against disease are provided. Delivery of the pharamacologically active molecules is provided at the mucosal surface, such as the gastric mucosa or nasal membranes, to provide effective and continuous delivery of a pharmacologically active agent. In some embodiments, the Helicobacter provides exposure of a desired molecule of interest though the surface of the Helicobacter, providing exposure of the antigen to the host at the gastric mucosa. Live Helicobacter pylori vaccines are also provided. Vectors and shuttle vector constructs of the Helicobacter are also disclosed.Type: GrantFiled: September 2, 2011Date of Patent: April 16, 2013Assignee: Ondek Pty. Ltd.Inventor: Barry J. Marshall
-
Patent number: 8298527Abstract: Helicobacter based preparations comprising a pharmacologically active molecule of interest are disclosed, as well as methods of preparing and using said preparations. In particular, Helicobacter pylori vectors, vector plasmids and recombinant cells that include a sequence encoding a pharmacologically active molecule of interest useful in therapeutic treatments and/or vaccination against disease are provided. Delivery of the pharamacologically active molecules is provided at the mucosal surface, such as the gastric mucosa or nasal membranes, to provide effective and continuous delivery of a pharmacologically active agent. Vectors and shuttle vector constructs are also provided.Type: GrantFiled: April 29, 2011Date of Patent: October 30, 2012Assignee: Ondek Pty. Ltd.Inventor: Barry J. Marshall
-
Patent number: 8298806Abstract: Helicobacter based preparations comprising a pharmacologically active molecule of interest are disclosed, as well as methods of preparing and using said preparations. In particular, Helicobacter pylori vectors, vector plasmids and recombinant cells that include a sequence encoding a pharmacologically active molecule of interest useful in therapeutic treatments and/or vaccination against disease are provided. Delivery of the pharamacologically active molecules is provided at the mucosal surface, such as the gastric mucosa or nasal membranes, to provide effective and continuous delivery of a pharmacologically active agent. Vectors and shuttle vector constructs are also provided.Type: GrantFiled: May 14, 2009Date of Patent: October 30, 2012Assignee: Ondek Pty. Ltd.Inventor: Barry J. Marshall
-
Publication number: 20120225454Abstract: The present invention relates to synthetic operons. In particular, the present invention relates to a synthetic operon for integration into a bacterial chromosome of a bacterium comprising a promoter operably-linked to at least two genes, wherein at least one gene is a gene of interest and at least one gene is a gene essential to said bacterium.Type: ApplicationFiled: June 25, 2010Publication date: September 6, 2012Applicant: ONDEK PTY LTDInventors: Mohammed Benghezal, Yakhya Dieye, Carola Schwann, Miriam Sehnal, Alma Fulurija, Barry J. Marshall